MENU
+Compare
EXEL
Stock ticker: NASDAQ
AS OF
Jun 13 closing price
Price
$41.59
Change
-$0.19 (-0.45%)
Capitalization
11.34B

EXEL Exelixis Forecast, Technical & Fundamental Analysis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more

Industry: #Biotechnology
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EXEL with price predictions
Jun 12, 2025

EXEL in upward trend: price expected to rise as it breaks its lower Bollinger Band on June 11, 2025

EXEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where EXEL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

EXEL moved above its 50-day moving average on May 14, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 282 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EXEL moved out of overbought territory on May 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EXEL as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EXEL turned negative on May 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.322) is normal, around the industry mean (16.730). P/E Ratio (18.991) is within average values for comparable stocks, (59.666). Projected Growth (PEG Ratio) (2.598) is also within normal values, averaging (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (5.280) is also within normal values, averaging (257.556).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EXEL is expected to report earnings to rise 2.65% to 63 cents per share on August 12

Exelixis EXEL Stock Earnings Reports
Q2'25
Est.
$0.64
Q1'25
Beat
by $0.25
Q4'24
Beat
by $0.16
Q3'24
Beat
by $0.13
Q2'24
Beat
by $0.53
The last earnings report on May 13 showed earnings per share of 62 cents, beating the estimate of 37 cents. With 2.13M shares outstanding, the current market capitalization sits at 11.34B.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KAPA0.570.08
+16.16%
Kairos Pharma Ltd.
BRC69.470.12
+0.17%
Brady Corp
NOVA0.22N/A
N/A
Sunnova Energy International
MYFW20.81-0.10
-0.48%
First Western Financial
H133.06-1.31
-0.97%
Hyatt Hotels Corp

EXEL and Stocks

Correlation & Price change

A.I.dvisor tells us that EXEL and RIGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and RIGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+0.84%
RIGL - EXEL
29%
Poorly correlated
+0.52%
ACLX - EXEL
29%
Poorly correlated
+0.51%
RVMD - EXEL
28%
Poorly correlated
+0.78%
UTHR - EXEL
28%
Poorly correlated
+3.50%
CGON - EXEL
28%
Poorly correlated
+1.22%
More